ERBB2 and cancer: Targeting HER2 with various therapeutic antibodies, e.g., trastuzumab (TZM) and pertuzumab, as well as antibody–drug conjugates (T-DM1) has led to a dramatic improvement in survival outcomes for HER+ cancer patients [2,3,4].